Background: There is demonstrated benefit with fluoroquinolones as infection prophylaxis in neutropenic patients; however, side effects, drug interactions and increasing resistance necessitate investigation of alternative therapies.
Introduction
Bacterial infections following chemotherapy are a major cause of treatment complications and death in patients with haematological cancers. [1] [2] [3] [4] Antimicrobial prophylaxis with fluoroquinolones has demonstrated a reduced incidence of neutropenic fever, infection rates, hospitalization rates and length of hospital stay in this patient population. [1] [2] [3] [4] [5] [6] A recent systematic review and metaanalysis showed that use of antimicrobial prophylaxis during chemotherapy-induced neutropenia reduces mortality. 5 The guidelines from the IDSA and the National Comprehensive Cancer Network (NCCN) recommend the consideration of either levofloxacin or ciprofloxacin for infection prophylaxis in high-risk patients. 1, 2 A major limitation to prescribing fluoroquinolones as prophylaxis during chemotherapy-induced neutropenia is the emergence of bacterial resistance, including MDR organisms. 5, [7] [8] [9] [10] [11] [12] [13] Additional concerns surround the increasing prevalence of Gram-negative organisms causing bloodstream infections, where Escherichia coli was the most frequent, followed by Pseudomonas aeruginosa and then Klebsiella pneumoniae. This re-emergence is clinically V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. important due to the increased mortality, hospital cost and treatment failure in bloodstream infections caused by antimicrobialresistant Gram-negative bacteria. 11 The increase in antimicrobialresistant Gram-negative bacilli questions the utility, preferred agent and duration of antimicrobial prophylaxis during chemotherapy-induced neutropenia. 8, [14] [15] [16] Oral third-generation cephalosporins have antibacterial activity against Gram-negative bacteria and Gram-positive penicillinaseproducing bacteria. [17] [18] [19] Oral third-generation cephalosporins have been substituted as neutropenic prophylaxis on a case-bycase basis when a fluoroquinolone could not be administered due to intolerances, allergies, history of adverse drug reactions or drug-drug interactions. 20 Specifically, cefpodoxime was observed to be safe as neutropenic prophylaxis without significantly affecting the resistance profile to empirical broad-spectrum therapy in a limited retrospective case series involving patients with haematological malignancies undergoing HSCT or intensive chemotherapy. 20 The cohort design of this single-centre study necessitates a comparator group to validate the use of oral third-generation cephalosporins as antibacterial prophylaxis in this high-risk patient population.
This purpose of this study was to compare the incidence of febrile neutropenia in high-risk patients with haematological malignancy receiving a fluoroquinolone as antibacterial prophylaxis during chemotherapy-induced neutropenia with those receiving an oral third-generation cephalosporin. Of additional interest was the incidence of bacterial infection between prophylactic agents, the morphology and species of organisms recovered from positive cultures and the appropriateness of the empirical febrile neutropenia treatment regimen.
Methods

Study design and population
Consecutive adult patients with AML and intermediate or high-risk myelodysplastic syndrome (MDS) receiving antibacterial chemoprophylaxis at the Mayo Clinic between January 2006 and April 2016 were evaluated. Patients were included if they were 18 years or older, received induction or first relapse induction-remission chemotherapy regimens and then subsequently were prescribed a fluoroquinolone (500 mg of levofloxacin daily) or an oral third-generation cephalosporin (300 mg of cefdinir twice daily or 200 mg of cefpodoxime twice daily) dosed according to renal function as antibacterial prophylaxis for anticipated profound and prolonged neutropenia. Data from the course of antibacterial prophylaxis were collected on only the first episode of febrile neutropenia (if any) documented.
Ethics
This retrospective chart review was approved by the Mayo Clinic Institutional Review Board (IRB: 15-007509) and conducted at the Mayo Clinic, Rochester, MN, USA. All included patients provided consent for review of their medical records for research purposes.
Data collection
Data were managed using REDCap (Research Electronic Data Capture) tools hosted at the Mayo Clinic. REDCap is a secure, web-based application designed to support data capture for research studies, providing: (i) an intuitive interface for validated data entry; (ii) audit trails for tracking data manipulation and export procedures; (iii) automated export procedures for seamless data downloads to common statistical packages; and (iv) procedures for importing data from external sources. 21 Baseline demographics, disease characteristics and laboratory values were abstracted from the medical record between date of admission and prior to the administration of antimicrobial prophylaxis. The Charlson comorbidity risk index was calculated on the day prior to the first dose of antibacterial prophylaxis. 22 Reasons for oral third-generation agents as prophylaxis instead of a fluoroquinolone were recorded as corrected QT prolongation, tendon rupture, glucose intolerance, gastrointestinal disturbance, history of a fluoroquinolone-resistant organism, rash, anaphylaxis, decreased blood pressure, tendonitis, seizure, nightmares/delusions and other.
Patient records were reviewed from the start of antimicrobial prophylaxis up to the soonest of 30 days from the last dose of neutropenia prophylaxis, the date of consolidation chemotherapy regimen administration, or death. Neutropenia was defined in accordance with IDSA guidelines as an absolute neutrophil count (ANC) of ,500 cells/mm 3 or an ANC that is expected to decrease to ,500 cells/mm 3 during the next 48 h. 1 Fever was defined as a single oral temperature measurement of 38.3 C (101 F) or a temperature of 38 C (100.4 F) sustained over 1 h. 1 Clinical outcomes were recorded after febrile episodes and included the prescribed empirical antimicrobial treatment regimen, admission to the ICU, need for vasopressors, need for mechanical ventilation and need for dialysis. Microbiological outcomes included the site of infection, morphology and species of isolated microorganism and antibiotic susceptibility profile. Intermediate (I) susceptibility was categorized as non-susceptible. Empirical antimicrobial therapy was determined to be appropriate if the recovered organism was susceptible to at least one of the initial broad-spectrum agents prescribed.
To adjust for the potential confounding between groups, patients were individually matched by cephalosporin versus fluoroquinolone in a 1:2 ratio, respectively, using age (+5 years) and the Charlson comorbidity index (+3) as the matching factors. Kaplan-Meier methodology was used to estimate the cumulative incidence of fever and infections during chemotherapyinduced neutropenia. Stratified Cox proportional hazards models, with matched sets as the strata, were used to estimate the association between prophylaxis type and fever. The HR comparing prophylaxis groups with a 95% CI was computed. Stratified logistic regression models were used to assess the associations between baseline variables and prophylaxis groups. The v 2 test and Fisher's exact test were used to compare site of infection and microorganisms recovered in culture-positive cases of febrile neutropenia between prophylaxis groups. Based on the observed 108 patients who developed a fever in this study and a 1:2 group ratio, we had 80% power to detect an HR of 1.78 with a two-sided test at a " 0.05. All analyses were carried out using the SAS statistical software package (Version 9.4, SAS Institute, Cary, NC, USA).
Results
A total of 565 patients admitted to the Mayo Clinic inpatient leukaemia service for chemotherapy and concurrently prescribed antibacterial prophylaxis with either levofloxacin or an oral thirdgeneration cephalosporin were screened between 1 January 2006 and 1 April 2016. Of those screened, 397 patients met the inclusion criteria, with 40 patients receiving an oral third-generation cephalosporin and 357 receiving levofloxacin. Matching via Charlson comorbidity index and age resulted in 120 patients (40 on an oral third-generation cephalosporin and 80 on levofloxacin prophylaxis) for analysis. Reasons for exclusion are described in Figure 1 and predominately included a haematological cancer diagnosis other than AML or MDS and lack of infection prophylaxis being prescribed after receiving chemotherapy. Patient characteristics of Antibacterial prophylaxis comparison JAC the matched sample are presented in Table 1 . Of the 120 study patients, 78 (65%) were male and the median age was 58.6 years (IQR " 53.3-68.1 years). The sample comprised 112 (93.3%) patients with AML and 8 (6.7%) patients with MDS. The most commonly prescribed chemotherapy regimen was an anthracycline in combination with cytarabine. Other regimens included: (i) a tyrosine kinase inhibitor (nilotinib) in combination with an anthracycline and cytarabine, and (ii) clofarabine with or without cytarabine. Approximately half the patients from each group required reinduction chemotherapy with an appropriate regimen for the treatment of their disease. There were no statistically significant associations with the baseline characteristics. Six patients (5%) received cefpodoxime and 34 patients (28.3%) received cefdinir as febrile neutropenia prophylaxis after chemotherapy. Documented reasons for patients not receiving an oral fluoroquinolone were QTc prolongation (35.1%), rash (21.6%), tendonitis (2.7%), anaphylaxis (2.7%), resistant organism (2.7%), drug interaction with a treatment study drug (24.3%) or other (10.8%).
Incidence of febrile neutropenia and clinical outcomes
There were a total of 108 patients who had a documented febrile episode. By 30 days after prophylaxis start, 106 of the 120 patients developed febrile neutropenia (89.7%, 95% CI " 82.4-93.9, by 30 days). Figure 2 displays the comparison of febrile neutropenia incidence between prophylaxis groups. The incidence of febrile episode by group was 32 for cephalosporins (83.4%, 95% CI " 65.8-91.9, by 30 days) and 74 for levofloxacin (92.5%, 95% CI " 83.8-96.5, by 30 days) and was similar between groups (cephalosporins versus levofloxacin, HR " 0.90, 95% CI " 0.54-1.52, P " 0.70). The mean ANC value at the time of febrile neutropenia was 473 cells/mm 3 (SD " 1437 cells/mm 3 ). The median duration of neutropenia was similar between groups, with a median duration of 46 days (IQR " 26-67 days) and 39 days (IQR " 27-49 days) for patients receiving oral third-generation cephalosporins and levofloxacin, respectively (P " 0.83). Additionally, the duration of prophylaxis was similar between groups prior to fever, with patients receiving oral third-generation cephalosporins for a median of 8 days (IQR " 6-12 days) compared with 8.5 days (IQR " 5-13.5 days) for levofloxacin (P " 0.83). Fifteen (12.5%) of the patients were admitted to the ICU during hospitalization, with significantly more patients who received oral third-generation cephalosporins (n " 9) needing admission than levofloxacin (n " 9) (P " 0.040). A majority of the ICU admissions had positive line-related cultures with Gram-positive organisms. Three patients (2.5%) underwent dialysis, two (1.7%) required mechanical ventilation and two (1.7%) required vasopressor assistance. Three patients died during follow-up, with two patients being in the oral third-generation cephalosporin group and one patient being in the levofloxacin group (from first dose up to 30 days after the Yemm et al. Antibacterial prophylaxis comparison JAC last dose) (30 day survival " 99.2%, 95% CI " 97.5-100); two of the reported deaths were attributable to infection, with one death being in the oral third-generation cephalosporin group and one death being in the levofloxacin group.
Microbiological outcomes
Of the 108 patients who had a documented febrile episode, 39 (36.1%) developed positive cultures during infection workup. Gram-positive organisms alone comprised 28 (71.8%) of the positive cultures, 8 (20.5%) cultures were positive for Gramnegative organisms alone, 2 (5.1%) contained both Grampositive and Gram-negative organisms and 1 (2.6%) culture produced an anaerobic organism. There were 5 (12.8%) polymicrobial cultures and 34 (87.2%) monomicrobial cultures. The majority of the patients (61.5%) had an implanted central venous catheter as the positive culture site. The breakdown of recovered organisms, select antibiotic resistance and colonization is reported in Table 2 . Notably, there were two (5.1%) Pseudomonas infections in total, with one (4%) occurring in the fluoroquinolone prophylaxis group and one (7.1%) in the oral third-generation cephalosporin group. There were no significant differences between groups in terms of site of infection (P " 0.91) and morphology of recovered microorganism (P " 0.74). There were significantly more cultures positive for Enterobacter spp. in the oral third-generation cephalosporin group than in the levofloxacin group (P " 0.043), with no other significant differences when comparing the other recovered species. Empirical antimicrobial therapy for febrile neutropenia was appropriate 85% of the time. A combination of cefepime and vancomycin was the most commonly prescribed empirical antimicrobial treatment regimen. Meropenem in combination with vancomycin and piperacillin/tazobactam in combination with vancomycin were the next two commonly occurring regimens prescribed as empirical treatment for febrile neutropenia. The six patients in whom the initial broad-spectrum therapy was not appropriate comprised the following: one patient with a polymicrobial pulmonary culture positive for Stenotromonas maltophilia; three patients with linerelated cultures positive for VRE, and two patients who were started on cefepime monotherapy and had blood cultures positive for Bacillus spp. and Leptotrichia spp.; the urine culture of one of these two patients was positive for an MDR Pseudomonas spp. isolate that was meropenem non-susceptible. Antimicrobial regimens were all modified within 48 h to provide appropriate coverage targeted towards all organisms recovered in culture.
Discussion
Our single-centre, retrospective study describes a high overall incidence (90%, by 30 days after drug initiation) of febrile episodes in consecutive adult AML or high-risk MDS patients prescribed levofloxacin or an oral third-generation cephalosporin as antibacterial prophylaxis during chemotherapy-induced neutropenia with no difference between groups. The 39 cultures that returned positive during investigation most commonly revealed Gram-positive organisms and originated from a central venous catheter-related source. Empirical antimicrobial therapy was appropriate in a majority of cases; an antipseudomonal broad-spectrum antibiotic was generally combined with vancomycin for resistant Grampositive organism coverage. Yemm et al.
Current practice surrounding bacterial infection prophylaxis during chemotherapy-induced neutropenia largely consists of a single-class strategy using fluoroquinolones without mention of alternative agents for those unable to receive fluoroquinolones. 1, 2 The use of fluoroquinolones as antibacterial prophylaxis increases the risk of infections with MDR Gram-negative bacilli in cancer patients presenting with neutropenic fever after chemotherapy. 4, 7 Additionally, levofloxacin has been associated with adverse events ranging from transient gastrointestinal disturbances to lifethreatening glycaemic alterations and cardiac arrhythmias. 23, 24 These negative consequences of fluoroquinolone administration compel evaluation of other strategies, including the use of alternative agents as antibacterial prophylaxis in such a high-risk and vulnerable population. 20, [25] [26] [27] [28] There has been limited documented experience with prolonged oral third-generation cephalosporin use concurrently with chemotherapy. To date, studies have primarily consisted of small, descriptive studies primarily examining oral third-generation cephalosporin administration with irinotecan in solid tumours. Prolonged use of oral third-generation cephalosporins demonstrated high tolerability and enabled an increase in the maximum tolerated dose of concomitantly administered irinotecan. 29, 30 Coadministration of irinotecan with cefixime or cefpodoxime seemed to ameliorate chemotherapy-induced diarrhoea, allowing greater dose escalation with increased tolerability. One small case series examined oral cefpodoxime as antimicrobial prophylaxis during the period of neutropenia in adults with haematological malignancy undergoing intensive chemotherapy. This study Oral third-generation cephalosporin antibiotics notably lack coverage of Acinetobacter spp. and Pseudomonas spp., which is dissimilar to the fluoroquinolone standard of care. Notably, there were no Acinetobacter spp.-positive cultures reported in either group during our investigation. Of the culture-positive infections, one (7.1%) was positive for Pseudomonas spp. in the oral third-generation cephalosporin group compared with one (4%) in the fluoroquinolone group. The percentages are slightly increased from the historically reported culture positivity of Pseudomonas spp. infection, which is 1.8% with levofloxacin prophylaxis. 3, 4, 20 However, given the differences between study designs and patient populations along with the knowledge that there was only one positive culture per group, it is difficult to draw meaningful conclusions. Larger, more rigorous investigations are needed to determine the true incidence of Pseudomonas spp. infections if oral third-generation cephalosporins are to be utilized as antibacterial prophylaxis during the neutropenic period following chemotherapy.
The one organism to show a statistical increase in positive cultures was Enterobacter spp. This is not surprising as the association between recent b-lactam antibiotic administration and consequent Enterobacter spp. infection is well established. 31, 32 Additionally, the same exposure has more recently been associated with infections caused by chromosomally mediated AmpCproducing Enterobacteriaceae. 33 As there has been a significant increase in antimicrobial resistance rates exhibited by Enterobacter cloacae and delays in appropriate antimicrobial therapy active against these infections increase mortality, the epidemiology and resistance profiles should be monitored periodically to modify the empirical antimicrobial regimen if necessary. [33] [34] [35] Cefepime has demonstrated success against Enterobacter spp. infection. 36 The organisms recovered in our study were mostly susceptible to our standard empirical febrile neutropenia broad-spectrum antibacterial regimen, where cefepime is generally our preferred agent, with or without vancomycin. Fortunately, none of the 'inappropriate' regimens involved treatment of an eventual positive culture for Enterobacter spp.
Our study has several limitations for discussion. Strict inclusion criteria and a fluoroquinolone as our institutional standard of care led to only 40 patients receiving an oral third-generation cephalosporin in our population. However, patients were included consecutively and over an extended time frame to maximize accrual. Additionally, we feel that the chosen methodology of matching patients to those with similar characteristics receiving fluoroquinolones permitted appropriate comparison despite the retrospective and non-randomized design. The incidence of febrile neutropenia and infection rate in our study were consistent with historical data, increasing the applicability of our results. Another limitation is the institutional formulary modification changing oral thirdgeneration cephalosporin agents from cefpodoxime to cefdinir. These agents should not dramatically alter breakthrough infection profiles, as the antibacterial spectrum of coverage is very similar. Lastly, we included patients who switched antibacterial agents prior to study entry, both from ,48 h of empirical broad-spectrum antibacterial treatment dosing to a prophylaxis agent and also from ,48 h using levofloxacin as prophylaxis agent to an oral third-generation cephalosporin prophylaxis agent. This affected ,20% of our patients; however, we are unsure of the impact of these therapies on the epidemiology of the organisms in positive culture or their respective resistance patterns. We attempted to eliminate any confounding effects of potential changes to the microbiome or breakthrough infection due to lack of coverage from the use of previous agents by excluding patients who developed an active infection within 48 h after any antibacterial agent switch. On diagnosis patients often present with fever and broad-spectrum antibiotics are initiated prior to the transition of antibacterial prophylaxis in the setting of chemotherapy-induced neutropenia. We felt that allowing these inclusion criteria, while not ideal, were still applicable as it represents an accurate depiction of prescribing practices at our institution and elsewhere.
Conclusions
To the authors' knowledge, this is the only comparative study between a fluoroquinolone and oral third-generation cephalosporins for infection prophylaxis in patients with haematological malignancy. Our results show that oral third-generation cephalosporin agents, specifically cefpodoxime and cefdinir, appear safe alternatives when a patient presents with an intolerance to the fluoroquinolone standard of care. Further, rigorous, prospective studies are necessary to determine the utility and place of oral thirdgeneration cephalosporins for antibacterial prophylaxis in high-risk patients undergoing intensive chemotherapy for their haematological malignancy given the higher likelihood of ICU admission, the lack of antipseudomonal activity, an increase in cultures positive for Enterobacter spp. and potentiation of additional infections, particularly Clostridium difficile.
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